Abstract
In recent years, a new and very promising form of immunotherapy has emerged, i.e., adoptive T cell therapy. The current standard treatment requires autologous adoptive cell transfer, which is rather expansive and time-consuming. To generate universal and more potent modified T cells, gene-editing technologies (such as ZFNs, TALENs and CRISPR–Cas9 system) have recently been applied.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
